12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xarelto rivaroxaban regulatory update

Johnson & Johnson disclosed in its 3Q13 earnings that it submitted responses in August to complete response letters issued by FDA for Xarelto rivaroxaban to reduce the risk of secondary cardiovascular events and stent thrombosis in patients with acute coronary syndrome (ACS). The PDUFA dates are in mid-February, though specific dates are not disclosed. J&J...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >